NCT02076100View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 27, 2014

Primary Completion Date

November 15, 2015

Study Completion Date

November 15, 2015

Conditions
Hepatitis C Infection
Interventions
DRUG

Ruzasvir

Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02076100 - Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003) | Biotech Hunter | Biotech Hunter